Finally, it can be emphasized that aptamer is a good modality to treat macular diseases as shown first by the approved anti-VEGF aptamer (Macugen®, Eyetech Pharmaceuticals, New York, NY) [31] in nAMD and as evidenced by this study and the recent development of anti-C5 aptamer (Zimura®, IVERIC bio Inc, New York, NY) [32] in dry AMD. This evidence concerns the gene VEGFA and dry age related macular degeneration.